Toronto Dominion Bank Sells 1,392 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Toronto Dominion Bank reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 2.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,267 shares of the medical research company’s stock after selling 1,392 shares during the quarter. Toronto Dominion Bank’s holdings in IQVIA were worth $11,474,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc boosted its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in shares of IQVIA in the second quarter worth $27,000. Itau Unibanco Holding S.A. bought a new stake in IQVIA during the second quarter valued at $29,000. Rise Advisors LLC purchased a new position in IQVIA during the first quarter worth about $31,000. Finally, Riverview Trust Co purchased a new stake in shares of IQVIA in the 1st quarter valued at about $32,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.60% of the stock is owned by company insiders.

IQVIA Stock Performance

NYSE:IQV opened at $234.56 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm has a market cap of $42.74 billion, a PE ratio of 32.04, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The business has a 50 day moving average price of $241.29 and a 200-day moving average price of $233.69.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on IQV. Morgan Stanley upped their price objective on shares of IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group started coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective on the stock. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Friday. UBS Group upped their price objective on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, Truist Financial raised their price objective on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.